CT-707

DRUG3 trials

Sponsors

Centaurus Biopharma Co., Ltd., Shouyao Holdings (Beijing) Co. LTD

Conditions

Advanced Pancreatic CancerAdvanced Solid TumorNon-small Cell Lung Cancer

Phase 1

Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

Centaurus Biopharma Co., Ltd.Non-small Cell Lung Cancer

Start: 2016-03-31End: 2018-03-31Target: 40Updated: 2017-03-09

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Shouyao Holdings (Beijing) Co. LTDAdvanced Pancreatic Cancer

Start: 2022-08-11End: 2024-08-11Target: 114Updated: 2023-11-22

Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation

Not yet recruitingNCT06970132

Shouyao Holdings (Beijing) Co. LTDAdvanced Solid Tumor

Start: 2025-06-30End: 2028-12-31Target: 102Updated: 2025-05-14

Related Papers

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

BMC Medicine2022-11-2316 citations